Skip to main content

Immunohistochemistry Validation: Past, Present and Future

Validation procedures are part of the regulatory process in a laboratory setting.  Understanding the basic principles and reasons for validation is important for laboratory compliance of regulations and eventually for patient diagnosis and treatments of diseases.  A discussion of current trends and changes with the latest CAP checklist will be reviewed and future direction of where IHC validation may end up will be discussed.

Learning Objectives

  1. Understanding of the basic principles and reasons for the validation process.
  2. Describe historical perspective of past IHC validation requirements.
  3. Discuss current trends and changes in validation requirements (CAP latest checklist).
  4. Examine the future direction of where the IHC validation process may end up.

About the presenter

Philip Ferguson , M.D.

Dr. Philip Ferguson is in a private practice located in Arkansas. He has a diverse training background that includes an undergraduate degree in mechanical engineering, post-graduate training in internal medicine, and board certifications in anatomic pathology, clinical pathology, and hematopathology. His professional interests center around educational resource development for pathologists and trainees, and use of immunohisochemistry and molecular diagnostics in surgical pathology. Dr. Ferguson launched one of the first widespread internet educational tools for pathology residents to prepare for their board examination, PathMD (www.PathMD.com), which is now the Leica tool PathLead. Dr. Ferguson also serves as a state commissioner for the College of American Pathologists' Accreditation and Laboratory Improvement Program and is also member of the Global Advisory Board for Leica Biosystems. Dr. Ferguson has published several publication of late including ‘The Effect of Decalcification Solutions on Kappa and Lambda In-Situ Hybridization,’ as well as ‘Effects of Decalcification on Immunohistochemistry Comparing: Immunocal®, Formical2000®, and EDTA Stat®.’

El contenido de Leica Biosystems Knowledge Pathway está sujeto a las condiciones de uso del sitio web de Leica Biosystems, disponibles en: Aviso legal.. El contenido, incluidos los webinars o seminarios web, los recursos de formación y los materiales relacionados, está destinado a proporcionar información general sobre temas concretos de interés para los profesionales de la salud y no está destinado a ser, ni debe interpretarse como asesoramiento médico, normativo o jurídico. Los puntos de vista y opiniones expresados en cualquier contenido de terceros reflejan los puntos de vista y opiniones personales de los ponentes/autores y no representan ni reflejan necesariamente los puntos de vista ni opiniones de Leica Biosystems, sus empleados o sus agentes. Cualquier enlace incluido en el contenido que proporcione acceso a recursos o contenido de terceros se proporciona únicamente por comodidad.

Para el uso de cualquier producto, debe consultarse la documentación correspondiente del producto, incluidas las guías de información, los prospectos y los manuales de funcionamiento.

Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.